Unibest

Pharmaceutical intermediates

Venetoclax Intermediates

3 pharmaceutical intermediates for Venetoclax. Indication: Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell.

提交项目All intermediates

About Venetoclax

Originator
AbbVie
Indication
Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell
Approved Date
04/11/2016
DS/DP
05/26/2030

Available intermediates

3 intermediates currently listed for Venetoclax. Request specifications, documentation or a quotation for any item below.

Venetoclax intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine1228780-72-0//
Methyl 4-Fluoro-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzoate1235865-75-4//
3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide1228779-96-1//

Other programs under V

Valbenazine Tosylate (NBI-98854)Varenicline TartrateVelpatasvirVericiguatVibegronVilazodone HydrochlorideVONOPRAZAN FUMARATEVoxelotor

Building toward Venetoclax?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →